Lunai Bioworks (NASDAQ:LNAI) Stock Price Down 2.1% – What’s Next?

Lunai Bioworks Inc. (NASDAQ:LNAI)’s stock price traded down 2.1% during trading on Thursday . The company traded as low as $2.34 and last traded at $2.35. Approximately 39,837 shares were traded during mid-day trading, a decline of 92% from the average session volume of 488,892 shares. The stock had previously closed at $2.40.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on LNAI. Wall Street Zen upgraded Lunai Bioworks to a “sell” rating in a report on Saturday, May 23rd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Lunai Bioworks in a research note on Wednesday, July 8th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company has an average rating of “Sell”.

Lunai Bioworks Price Performance

The firm has a market capitalization of $10.74 million, a P/E ratio of -5.92 and a beta of 0.41. The firm’s fifty day moving average price is $2.66 and its 200-day moving average price is $2.93.

Hedge Funds Weigh In On Lunai Bioworks

An institutional investor recently bought a new position in Lunai Bioworks stock. Millennium Management LLC acquired a new stake in shares of Lunai Bioworks Inc. (NASDAQ:LNAI) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 202,629 shares of the company’s stock, valued at approximately $288,000. Millennium Management LLC owned about 0.87% of Lunai Bioworks at the end of the most recent quarter. Institutional investors and hedge funds own 71.41% of the company’s stock.

About Lunai Bioworks

Enochian Biosciences, Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company’s lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection.